| Jennifer Steinkeler, MD | |
|
1493 Cambridge St, Cambridge, MA 02139 | |
| (617) 665-1298 | |
| Not Available |
| Full Name | Jennifer Steinkeler |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 1493 Cambridge St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326301235 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 274003 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Hospital - Needham | Needham, MA | Hospital |
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Beth Israel Deaconess Hospital Plymouth | Plymouth, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc | 4486567104 | 1344 |
| Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is | 6305749987 | 440 |
News Archive
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure.
DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 7 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275574899 PECOS PAC ID: 4486567104 Enrollment ID: O20040323000584 |
News Archive
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure.
DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 7 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure.
DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 7 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1245773308 PECOS PAC ID: 6305749987 Enrollment ID: O20170628003015 |
News Archive
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure.
DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Steinkeler, MD 1493 Cambridge St, Cambridge, MA 02139-1099 Ph: (617) 665-1298 | Jennifer Steinkeler, MD 1493 Cambridge St, Cambridge, MA 02139 Ph: (617) 665-1298 |
News Archive
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure.
DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 7 days ago
Donald Francis Romanelli, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn Street, Mount Auburn Hospital, Cambridge, MA 02138 Phone: 617-492-3500 | |
Dr. Carolyn Lamb, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Wyman 3, Cambridge, MA 02138 Phone: 617-499-5639 Fax: 617-499-5464 | |
Edward B Marianacci, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 617-499-5070 Fax: 617-499-5138 | |
James J Pollard, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Radiology, Cambridge, MA 02139 Phone: 617-665-1298 | |
Adam F Gustin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Radiology Department, Cambridge, MA 02139 Phone: 617-665-1240 | |
Hyewon Hyun, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 617-499-5070 Fax: 617-499-5138 | |
Nazli Erbay, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1599 |